Crizotinib treatment is clearly superior to chemotherapy in treating ALK positive NSCLC patients, with a PFS of 7.7 months[9] yet unfortunately, treatment with targeted therapy commonly leads to acquired resistance. Here, ALK is linked to non-small cell lung carcinoma.